Dr. Sanjay Singh is a seasoned global Pharma Leader with unique blend of Science and Business acquired over three decades of diverse experience across the entire value chain of NMEs, genetic and regenerative medicines, biosimilars, complex generics, vaccines, and IVDs. He has built strong business acumen having deep insights in the science and business through his distinguished tenures at global leading pharmaceutical companies.

Dr. Singh has demonstrated expertise in developing and executing robust business strategies and managing both micro and macroeconomic factors in leading several global projects and organizations. His contributions have been instrumental in driving the growth of companies, successfully building portfolios organically and inorganically through M&A, in-licensing, collaborations, joint ventures, and strategic partnerships.

Dr. Singh has served on the Board of the National Institute of Pharmaceutical Education and Research, appointed by the Hon'ble President of India, as well as the Narsee Monjee Institute of Management Studies. He has also contributed to the growth of companies like Artes Biotechnology GmbH and MuBio Products BV as a member of their Board of Directors.

In addition, Dr. Singh has steered the committees with prestigious organizations such as the Weizmann Institute of Science, Santiago Hospital, Viatris-Abbott, Biocon, Fujifilm Kyowa Kirin Biologics, Wuxi Biologics, Lupin, Merck Sharp & Dohme, Samsung Biologics, Israel Institute of Technology, Intrexon Biotech (Precigen Inc.), Apatech, MassBiologics, Maastricht University, York University, and ICGEB, where he has contributed significantly to various early- and late-stage projects. His close collaborations with global business leaders and nobel laureates have further enriched his strategic insights.

With his extensive experience and deep strategic insights, Dr. Singh is Re-imagining therapy through Cell and Gene Therapy making it affordable and accessible to save lives.